Bad deals, nasty numbers, big mistakes and the occasional triumph. It’s been one heck of a year for corporate Australia.

MSD and Moderna have kicked off another phase 3 trial of their personalised cancer vaccine V940 used alongside MSD's PD-1 inhibitor Keytruda, this time focusing on patients with earlier-stage ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

Thailand SET offers exposure to a diversified basket of stocks, which can be appealing for investors seeking broad market exposure. Investing in the index can be done through various methods such as ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. A set-off clause is a legal clause that gives a lender the authority to seize a debtor's ...

MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...